不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液肿瘤的潜在预后标志物：CD58
英文原题：A potential prognostic marker for hematologic neoplasms: CD58.
查看英文原题
A potential prognostic marker for hematologic neoplasms: CD58.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD58是一种广泛分布于组织细胞上的糖蛋白受体，与CD2结合，参与构成免疫突触（IS）并激活T/NK细胞。CD58的异常表达已被证明对血液肿瘤（包括白血病和淋巴瘤）的预后产生显著影响。此外，这种异常表达还与CAR细胞治疗中的耐药和免疫排斥相关。在本文中，我们将通过描述CD58在免疫细胞中的功能、其对血液肿瘤及CAR细胞治疗等免疫疗法的影响，来探讨CD58在血液肿瘤学中的未来。
展开英文摘要原文
CD58 is a glycoprotein receptor widely distributed on histiocytes that binds to CD2, that takes part in constituting the Immunological Synapses (IS) and activating T/NK cells. Aberrant expression of CD58 has been demonstrated to exert a significant impact on the prognosis of hematological tumors, including leukemia and lymphoma.
Furthermore, this aberrant expression has been associated with drug resistance and immune rejection in CAR cell therapy. In this article, we will explore the future of CD58 in hematological oncology by describing its function in immune cells, its impact on hematological oncology and immunotherapies such as CAR cell therapy.
论文信息
- 作者
- Cao J、Zhang Y、Yue N、Xiong S、Zhang S、Wu C
- 单位
- Department of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2025
- 原文标识
- PubMed 40365344 · DOI 10.3389/fonc.2025.1586842
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →